---
schema_version: "secwatch.filing_event.v1"
accession: "0001731122-24-001845"
form_type: "8-K"
ticker: null
cik: "0001708331"
company_name: "Virpax Pharmaceuticals, Inc."
filed_at: "2024-11-22T23:59:59+00:00"
generated_at: "2026-05-29T19:49:42.184532+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Virpax resolves Nasdaq delisting, appoints new director, extends NIH collaboration, posts positive Probudur results

## Summary
- On Nov 19, Virpax cured Nasdaq delisting notice by appointing Esha Randhawa as independent director and audit committee member.
- CEO Jatinder Dhaliwal entered contractor agreement; annual fee $200k plus milestone incentives tied to IND, trials, FDA approval.
- NIH/NCATS extended collaboration for NES100 intranasal enkephalin pain candidate, aiming for IND for acute/chronic non-cancer pain.
- Probudur minipig DRF study showed positive tolerance, no adverse effects; supports IND filing for long-acting bupivacaine formulation.

## SEC filing metadata
- accession: 0001731122-24-001845
- form_type: 8-K
- cik: 0001708331
- company_name: Virpax Pharmaceuticals, Inc.
- filed_at: 2024-11-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 3.01, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708331/000173112224001845/0001731122-24-001845-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708331/000173112224001845/e6163_8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001731122-24-001845
- JSON: https://secwatch.observer/filing/0001731122-24-001845.json
- Plain text: https://secwatch.observer/filing/0001731122-24-001845.txt

## Key facts
- Executive change
  Esha Randhawa was appointed as Independent Director at Virpax Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Independent Director
  source text: on November 19, 2024, the Board appointed Ms. Esha Randhawa to serve as an independent director of the Company, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708331/000173112224001845/0001731122-24-001845-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.